Pharmacotherapeutics for Advanced Practice: A Practical Approach, 5th Edition (Arcangelo et al.) | 2025 Exam Test Bank & Study Revision Guide | Complete Verified Questions & Answers

lOMoARcPSD|327 v 44 6 9
l1OM oARcPSD|327 v 441

v 69

, lOMoARcPSD|327 v441
v69




TABLE OF CONTENT
v v




o Chapter 1: Issues for the Practitioner in Drug Therapy
v v v v v v v v




o Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
v v v v v v v v




o Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
v v v v v v v v v v




o Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
v v v v v v v v v




o Chapter 5: Pharmacotherapy Principles in Older Adults
v v v v v v




o Chapter 6: Principles of Antimicrobial Therapy
v v v v v




o Chapter 7: Pharmacogenomics
v v




o Chapter 8: The Economics of Pharmacotherapeutics
v v v v v




o Chapter 9: Principles of Pharmacology in Pain Management
v v v v v v v




o Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
v v v v v v v v v




o Chapter 11: Cannabis and Pain Management
v v v v v




o Chapter 12: Dermatitis v v




o Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
v v v v v v v v v




o Chapter 14: Psoriasis v v




o Chapter 15: Acne Vulgaris and Rosacea
v v v v v




o Chapter 16: Ophthalmic Disorders
v v v




o Chapter 17: Otitis Media and Otitis Externa
v v v v v v




o Chapter 18: Hypertension v v




o Chapter 19: Hyperlipidemiav v




o Chapter 20: Chronic Stable Angina and Myocardial Infarction
v v v v v v v




o Chapter 21: Heart Failure
v v v




o Chapter 22: Arrhythmias v v




o Chapter 23: Respiratory Infections
v v v




o Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
v v v v v v v




o Chapter 25: Gastric, Functional and Inflammatory Bowel Disorders
v v v v v v v v




o Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
v v v v v v v v




o Chapter 27: Liver Diseases
v v v




o Chapter 28: Urinary Tract Infection
v v v v




o Chapter 29: Prostatic Disorders and Erectile Dysfunction
v v v v v v v




o Chapter 30: Overactive Bladder
v v v




o Chapter 31: Sexually Transmitted Infections
v v v v




o Chapter 32: Osteoarthritis and Gout
v v v v




o Chapter 33: Osteoporosis v v




o Chapter 34: Rheumatoid Arthritis
v v v




o Chapter 35: Headaches v v




o Chapter 36: Seizure Disorders
v v v




o Chapter 37: Alzheimer’s Disease
v v v




o Chapter 38: Parkinson Disease
v v v




o Chapter 39: Major Depressive Disorder and Bipolar Disorders
v v v v v v v




o Chapter 40: Anxiety Disorders
v v v




o Chapter 41: Sleep Disorders
v v v




o Chapter 42: Attention Deficit Hyperactivity Disorder
v v v v v




o Chapter 43: Substance Use Disorders
v v v v




o Chapter 44: Diabetes Mellitus
v v v




o Chapter 45: Thyroid and Parathyroid Disorders
v v v v v




o Chapter 46: Allergies and Allergic Reactions o
v v v v v v




vChapter 47: Human Immunodeficiency Virus o
v v v v v




vChapter 48: Organ Transplantation
v v v




o Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
v v v v v v




o Chapter 50: Anemias v v




o Chapter 51: Immunizations v v




o Chapter 52: Smoking Cessation
v v v




o Chapter 53: Weight Loss v v v




o Chapter 54: Contraception v v

, v441



Chapter 55: Menopause
lOMoARcPSD|327

v69


o v v




o Chapter 56: Vaginitis v v




Chapter 1 Issues for the Practitioner in Drug Therapy
v v v v v v v v




MULTIPLE CHOICEv




1. Nursepractitioner prescriptive authority is regulated by:
v v v v v v




A. The National Council of State Boards of Nursing
v v v v v v v




B. The U.S. Drug Enforcement Administration
v v v v




C. The State Board of Nursing for each state
v v v v v v v




D. The State Board of Pharmacy v v v v




ANS: C v PTS: 1

2. Physician Assistant (PA) prescriptive authority is regulated by:
v v v v v v v




A. The National Council of State Boards of Nursing
v v v v v v v




B. The U.S. Drug Enforcement Administration
v v v v




C. The State Board of Nursing v v v v




D. The State Board of Medical Examiners
v v v v v




ANS: D v PTS: 1

3. Clinical judgment in prescribing includes:
v v v v




A. Factoring in the cost to the patient of the medication prescribed v v v v v v v v v v




B. Always prescribing the newest medication available for the disease process
v v v v v v v v v




C. Handing out drug samples to poor patients v v v v v v




D. Prescribing all generic medications to cut costs v v v v v v




ANS: A v PTS: 1

4. Criteria for choosing an effective drug for a disorder include:
v v v v v v v v v




A. Asking the patient what drug theythink would work best for them
v v v v v v v v v v v




B. Consulting nationallyrecognized guidelines for disease management v v v v v v




C. Prescribing medications that are available as samples before writing a prescription v v v v v v v v v v




D. Following U.S. Drug Enforcement Administration (DEA) guidelines for v v v v v v v




v prescribing
ANS: B v PTS: 1

5. Nurse practitioner practice may thrive under health-care reform due to:
v v v v v v v v v




A. The demonstrated ability of nurse practitioners to control costs and improve patient
v v v v v v v v v v v




outcomes
v




B. Thefact that nurse practitioners willbe abletopractice independently
v v v v v v v v v v




C. The fact that nurse practitioners will have full reimbursement under health-care
v v v v v v v v v v




reform
v




D. The ability to shift accountability for Medicaid to thestate level
v v v v v v v v v v




ANS: A v PTS: 1

, lOMoARcPSD|327 v441
v69




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
v v v v v v




MULTIPLE CHOICE v




1. A patient’s nutritional intake and lab workreflects hypoalbuminemia. This is critical to
v v v v v v v v v v v v




prescribingbecause:
v




A. Distribution of drugs to target tissue may be affected v v v v v v v v




B. The solubility of the drug will not match the site of absorption
v v v v v v v v v v v




C. There will beless freedrug available togenerate aneffect
v v v v v v v v v v




D. Drugs bound to albumin are readily excreted bythe kidney
v v v v v v v v v




ANS: A v PTS: 1

2. Drugs that have a significant first-pass effect:
v v v v v v




A. Must be given bythe enteral (oral) route only
v v v v v v v v




B. Bypass the hepatic circulation v v v




C. Are rapidly metabolized by the liver and may have little if any desired action
v v v v v v v v v v v v v




D. Are converted by the liver to more active and fat-soluble forms
v v v v v v v v v v




ANS: C v PTS: 1

3. The route of excretion of a volatile drug will likelybe:
v v v v v v v v v v




A. The kidneys v




B. The lungs v




C. The bile and feces v v v




D. The skin v




ANS: B v PTS: 1

4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the v v v v v v v v v v v v




drug.Storagereservoirs:
v v v




A. Assure that the drug will reach its intended target tissue v v v v v v v v v




B. Are the reason for giving loading doses
v v v v v v




C. Increase the length of time a drug is available and active v v v v v v v v v v




D. Are most common in collagen tissues
v v v v v




ANS: C v PTS: 1

5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
v v v v v v v v v v v v v v




A. Propensity to go to the target receptor v v v v v v




B. Biologicalhalf-life v




C. Pharmacodynamics
D. Safetyand side effects v v v




ANS: B v PTS: 1

6. Azithromycin dosing requires thefirst day’s dose be twice those of the other 4 days ofthe
v v v v v v v v v v v v v v v v




prescription. This is considered a loading dose. A loading dose:
v v v v v v v v v v




A. Rapidly achieves drug levels in the therapeutic range v v v v v v v




B. Requires four to five half-lives to attain v v v v v v




C. Is influenced by renal function
v v v v